Journal
HEALTH AFFAIRS
Volume 24, Issue 1, Pages 67-78Publisher
PROJECT HOPE
DOI: 10.1377/hlthaff.24.1.67
Keywords
-
Funding
- NIAID NIH HHS [R37 AI 29168] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029168] Funding Source: NIH RePORTER
Ask authors/readers for more resources
There is interest in approaches allowing more rapid availability of new interventions, particularly for diseases providing risks of death or serious illness. The accelerated-approval regulatory process is intended to address this need by allowing marketing of interventions shown to have strong effects on measures of biological activity, if those measures are potential surrogates for true measures of tangible clinical benefit. To use surrogate endpoints and the accelerated-approval process, challenging issues must be addressed to avoid compromising what is truly in the best interest of public health: the reliable as well as timely evaluation of an intervention's safety and efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available